We found At-Risk participants to have a significantly higher frequency of cit-specific T cells than anti-CCP3(−) Controls; in addition, the frequency of cit-specific T cells was similar between At-Risk and Early RA participants (Fig. 2a). This evidence concerns the gene AGBL3 and rheumatoid arthritis.